Latest From Debiopharm Group
Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.
Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.
Novartis has returned all rights of Debiopharm's hepatitis C virus (HCV) compound alisporivir in line with the company's decision to pull out of HCV.
Novartis has decided to throw in the towel over hepatitis C. "As part of an ongoing portfolio transformation, hepatitis C virus (HCV) will no longer be a strategic focus," the pharma major has confirmed. As a result, Novartis has terminated its licensing agreement with Enanta Pharmaceuticals for the development of EDP239, an NS5A inhibitor currently in Phase I development for the treatment of HCV. However, "Ongoing trials in HCV will not be affected by this decision and these trials will be completed as planned," it added.
- Large Molecule
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Specialty Pharmaceuticals
- Therapeutic Areas
- Debio Group
- Western Europe
- Parent & Subsidiaries
- Debiopharm Group
- Senior Management
Rolland-Yves Mauvernay, Co-Pres.
Thierry Mauvernay, Co-Pres.
- Contact Info
Phone: (41) 21 321 0111
Chemin Messidor 5-7
P.O. Box 5911 Lausanne, CH-1002
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.